New 48-week results from Johnson & Johnson’s Phase IIIb APEX trial show Tremfya delivers durable symptom improvement, slows radiographic progression, and maintains a consistent safety profile in ...

Explore which factors—audience relevance, content fit, and engagement quality—determine the best use of platforms like TikTok ...

In today’s ACT Brief, we look at how real-world data and AI are helping prevent costly study rescue, review the FDA’s ...

FDA has approved Komzifti (ziftomenib) as the first once-daily, oral menin inhibitor for adults with relapsed or refractory NPM1-mutated AML, supported by Phase II KOMET-001 data showing meaningful ...

Data-driven planning aids in the design of feasible clinical trials from the outset, by simulating enrollment before the ...

In today’s ACT Brief, we examine declining site satisfaction and strategies to improve sponsor-site collaboration, review a ...

The ARTISTRY-1 Phase III trial demonstrated that a single-tablet regimen of bictegravir 75 mg/lenacapavir 50 mg maintains viral suppression and simplifies therapy for people living with HIV, ...

Advarra and IgniteData have announced a new partnership, enabling secure clinical data transfer between research sites’ instances of Advarra's eSource and electronic data capture (EDC) solutions, ...

How sponsors can leverage technology to enhance, not hinder, site efficiency and usability Strategies to incorporate site ...

As biotechs scale up, streamlining the planning, execution, and monitoring of outsourced clinical trials becomes critical. While CROs manage the day-to-day operations, sponsors are ultimately ...

As biotechs expand their outsourced clinical operations, adopting a CTMS is becoming essential to ensure CRO oversight, regulatory compliance, and real-time visibility across trials and portfolios.

Alixorexton, an investigational, oral, selective orexin 2 receptor agonist, demonstrated meaningful improvements across the trial’s dual primary endpoints of change from baseline in Maintenance of ...